These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 17701583)
1. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G Leuk Lymphoma; 2007 Aug; 48(8):1522-30. PubMed ID: 17701583 [TBL] [Abstract][Full Text] [Related]
2. Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G Leuk Lymphoma; 2007 Aug; 48(8):1539-47. PubMed ID: 17701585 [TBL] [Abstract][Full Text] [Related]
3. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965 [TBL] [Abstract][Full Text] [Related]
4. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992 [TBL] [Abstract][Full Text] [Related]
5. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235 [TBL] [Abstract][Full Text] [Related]
6. [The role of FDG-PET in staging of lymphoma and evaluation of therapeutic efficiency]. Zhou LL; Wang C; Zhao JH; Yan SK; Gao YR; Cai Q; Jiang JL; Wan LP; Yang J; Wei J; Zhao M; Bai HT Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):233-6. PubMed ID: 19731822 [TBL] [Abstract][Full Text] [Related]
7. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
9. Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin's lymphoma. CCHE experience. Abdel Rahman H; Sedky M; Hamoda A; Raafat T; Youssef A; Omar W; Hassanein O; Moussa E J Egypt Natl Canc Inst; 2016 Jun; 28(2):95-9. PubMed ID: 27133974 [TBL] [Abstract][Full Text] [Related]
10. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420 [TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. Jacene HA; Filice R; Kasecamp W; Wahl RL J Nucl Med; 2009 Jan; 50(1):8-17. PubMed ID: 19091903 [TBL] [Abstract][Full Text] [Related]
12. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863 [TBL] [Abstract][Full Text] [Related]
14. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522 [TBL] [Abstract][Full Text] [Related]
17. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas. Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687 [TBL] [Abstract][Full Text] [Related]
18. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169 [TBL] [Abstract][Full Text] [Related]